AR, a nuclear hormone receptor, drives the growth and survival of prostate cancer cells by mediating the effects of androgens.353 TPD, as a novel strategy for prostate cancer, degrades AR directly, and overcomes resistance. This evidence concerns the gene AR and prostate carcinoma.